Eli Lilly has called on financial regulators to look into the antitrust implications of Novo Holdings' purchase of Catalent and the sale of three manufacturing facilities
Novo Nordisk has taken the bold step of buying three manufacturing facilities from contract development and manufacturing organisation Catalent as it tries to meet surging
Fuelled by its diabetes and obesity drugs, Novo Nordisk has reported revenues up a third in 2023, sparking a rise in an already inflated share price that briefly pushed th
Eli Lilly is just weeks away from launching Mounjaro in the UK, after getting approval from medicines regulator, the MHRA, for a new formulation of the drug as a treatment
The FDA has given an update on its ongoing review of a possible link between GLP-1 agonist drugs used to treat diabetes and obesity and suicide, saying it can find no evid
Novo Nordisk has reaped the first harvest from its wide-ranging alliance with life sciences investor Flagship Pioneering, buying rights to two programmes from the VC’s por